

March 23, 2021

**VIA EDGAR**

U.S. Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549  
Attn: Jeanne Bennett  
Vanessa Robertson  
Kasey Robinson  
Jeffrey Gabor

**Re: Design Therapeutics, Inc.  
Registration Statement on Form S-1, as amended (File No. 333-253954)  
Request for Acceleration of Effective Date**

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the "Act"), we, as the representatives of the several underwriters, hereby join in the request of Design Therapeutics, Inc. (the "Company") for acceleration of the effective date of the above-referenced Registration Statement on Form S-1 so that it becomes effective at 4:00 p.m. Eastern time on March 25, 2021, or as soon thereafter as possible.

Pursuant to Rule 460 under the Act, we, as the representatives of the several underwriters, wish to advise you that between March 22, 2021 through the date hereof we have distributed approximately 2,749 copies of the Company's Preliminary Prospectus dated March 22, 2021 to prospective underwriters, dealers, institutional investors and others.

We, the undersigned, as the representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

(signature page follows)

Very truly yours,

GOLDMAN SACHS & CO. LLC  
SVB LEERINK LLC  
PIPER SANDLER & CO.

*Acting severally on behalf of themselves and the several  
underwriters*

GOLDMAN SACHS & CO. LLC

By: /s/ Elizabeth Wood

Name: Elizabeth Wood

Title: Managing Director

SVB LEERINK LLC

By: /s/ Stuart Nayman

Name: Stuart Nayman

Title: Managing Director, Senior Legal  
Counsel

PIPER SANDLER & CO.

By: /s/ Neil Riley

Name: Neil Riley

Title: Managing Director

*(Signature Page to Acceleration Request Letter)*